Medical disclaimer

The editorial portions of this site are educational, not medical advice or a recommendation to obtain or use DSIP. DSIP (emideltide) is not FDA-approved for any use; FDA has identified significant safety concerns and in July 2026 proposed excluding it from the 503A Bulks List. Separately, the DSIP care section is commercial, and DSIP Peptide may receive revenue from purchases initiated through its provider-review flow. The compounded product is not FDA-approved. Completing intake or payment does not guarantee a prescription; a licensed provider must determine whether treatment is appropriate. No named clinician has reviewed this site's editorial content. Research doses are historical facts, not instructions. Insomnia, narcolepsy and opioid withdrawal have approved treatment options; discuss your circumstances with a licensed clinician.